2 completed, 1 enrolling by invitation, 1 terminated. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Enrolling by invitation 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Enrolling by invitation 1 |
Follow Hereditary Angioedema Attack: new trials by email Literature Review of Hereditary Angioedema Attack trials Research Report on Hereditary Angioedema Attack
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 3 | Completed | Pharvaris Netherlands B.V. | 134 | 2024-02-26 | 2025-11-21 |
| Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 / Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 150 | 2022-12-28 | 2026-07-21 |
| Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II Deucrictibant low dose, Deucrictibant high dose, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Terminated | Pharvaris Netherlands B.V. | 34 | 2022-04-19 | 2026-08-17 |
| Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Completed | Pharvaris Netherlands B.V. | 74 | 2021-02-03 | 2025-12-17 |
Angioedemas, Hereditary (4) · Hereditary Angioedema Types I and II (4) · Hereditary Angioedema Type III (2)
Angioedema (4) · Cardiovascular Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Hereditary Complement Deficiency Diseases (4) · Hypersensitivity (4) · Hypersensitivity, Immediate (4) · Immune System Diseases (4) · Immunologic Deficiency Syndromes (4) · Primary Immunodeficiency Diseases (4) · Skin Diseases (4) · Skin Diseases, Vascular (4) · Skin and Connective Tissue Diseases (4) · Urticaria (4) · Vascular Diseases (4)
Pharvaris Netherlands B.V. (4)
Bulgaria (4) · Canada (4) · Germany (4) · Italy (4) · Poland (4) · United Kingdom (4) · United States (4) · Austria (3) · Czechia (3) · France (3) · Hungary (3) · Netherlands (3) · Spain (3) · Argentina (2) · Australia (2)
Marc Riedl, MD (1) · Marcus Maurer, Prof MD (1)
PMID 41865746, PMID 41865747, PMID 42849489
2023 (1)